2024    2023    2022    2021    2020    2019    2018    2017    2016   

2022

Articles avec comité de lecture de revues internationales

91 - 

Prevalence of HFE-related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection

Gérald Le Gac, Virginie Scotet, Isabelle Gourlaouen, Carine L'Hostis, Marie-Christine Merour, Zoubida Karim, Yves Deugnier, Edouard Bardou-Jacquet, Thibaud Lefebvre, Suzanne Assari, Claude Ferec

Alimentary Pharmacology and Therapeuthics, 2022, 55 (8), pp.1016-1027.

DOI : https://doi.org/10.1111/apt.16775

Pubmed : 35122291

 

92 - 

Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France

Soline Leblanc, Mathilde Lefort, Emmanuelle Le Page, Laure Michel, Emmanuelle Leray

Expert Review of Neurotherapeutics, 2022, 22 (5), pp.411-418.

DOI : https://doi.org/10.1080/14737175.2022.2061950

Pubmed : 35363999

 

93 - 

Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients

M. Lefort, G. Le Corre, E. Le Page, C. Rizzato, D. Le Port, L. Michel, A. Kerbrat, Emmanuelle Leray, G. Edan

Revue Neurologique, 2022, 178 (6), pp.569-579.

DOI : https://doi.org/10.1016/j.neurol.2021.11.014

Pubmed : 35181157

 

94 - 

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

M. Lefort, S. Sharmin, J. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. de Sèze, E. Maillart, H. Zephir, Pierre Labauge, G. Defer, C. Lebrun-Frenay, T. Moreau, E. Berger, P. Clavelou, J. Pelletier, B. Stankoff, O. Gout, Eric Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Wahab, J. Camdessanché et al.

BMC Medical Research Methodology, 2022, 22 (1), pp.155.

DOI : https://doi.org/10.1186/s12874-022-01623-8

Pubmed : 35637426

 

95 - 

Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments

Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray

European Journal of Neurology, 2022, 29 (9), pp.2761-2771.

DOI : https://doi.org/10.1111/ene.15422

Pubmed : 35617144

 

96 - 

Staphylococcus aureus endocarditis: Identifying prognostic factors using a method derived from morbidity and mortality conferences

Benjamin Lefèvre, Antoine Legoff, Mathilde Boutrou, François Goehringer, Willy Ngueyon-Sime, Catherine Chirouze, Matthieu Revest, Véronique Vernet Garnier, Xavier Duval, François Delahaye, Vincent Le Moing, Christine Selton-Suty, Laura Filippetti, Bruno Hoen, Nelly Agrinier

Frontiers in Medicine, 2022, 9, pp.1053278. ⟨hal-03921923v2⟩

DOI : https://doi.org/10.3389/fmed.2022.1053278

Pubmed : 36561723

 

97 - 

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients

Soizic Leguy, Mathilde Lefort, Lucile Lescot, Audrey Michaud, Sandra Vukusic, Emmanuelle Le Page, Gilles Edan, Anne Kerbrat, Christine Lebrun-Frenay, Jérôme de Sèze, David-Axel Laplaud, Sandrine Wiertlewski, Emmanuelle Leray, Laure Michel

Journal of Neurology, 2022, 269 (269), pp.5571-5581.

DOI : https://doi.org/10.1007/s00415-022-11215-7

Pubmed : 35737108

 

98 - 

Mega randomized clinical trials: a definitive solution or a double-edged sword?

Florian Lemaitre, Bruno Laviolle

European Journal of Clinical Pharmacology, 2022, 78 (2), pp.305-306.

DOI : https://doi.org/10.1007/s00228-021-03230-w

Pubmed : 34651199

 

99 - 

Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)

Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard

Therapies, 2022, 77 (5), pp.509-521.

DOI : https://doi.org/10.1016/j.therap.2022.03.005

Pubmed : 35618549

 

100 - 

Has the Time Come for Systematic Therapeutic Drug Monitoring of First-line and WHO Group A Anti-tuberculosis Drugs?

Florian Lemaitre

Has the Time Come for Systematic Therapeutic Drug Monitoring of First-line and WHO Group A Anti-tuberculosis Drugs?. Therapeutic Drug Monitoring, 2022, 44 (1), pp.133-137.

DOI : https://doi.org/10.1097/FTD.0000000000000948

Pubmed : 34857693